Bayer AG BAYRY submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for darolutamide for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).
The submission is based on data from the phase III ARAMIS study in men with nmCRPC showing a statistically significant improvement in metastasis-free survival (MFS) for darolutamide plus androgen deprivation therapy (ADT). Darolutamide plus ADT has shown a favorable safety profile compared to placebo plus ADT.
Shares of Bayer have declined 34.3% in the past year against the industry’s growth of 9.6%.
In February 2019, Bayer completed the rolling submission of a new drug application (NDA) for darolutamide to the FDA. The company has also submitted an application for marketing authorization to the Ministry of Health, Labor and Welfare (MHLW) in Japan for darolutamide for the treatment of patients with castration-resistant prostate cancer (CRPC). Bayer is also in discussions with other health authorities regarding submissions.
Bayer has been granted Fast Track designation by the FDA for darolutamide in men with nmCRPC. The compound is being developed jointly by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company.
We note that another company, Johnson & Johnson’s JNJ Erleada was approved in EU in January 2019 for the treatment of nmCRPC who are at high risk of developing metastatic disease. It is presently marketed in the United States for the same indication.
Bayer Aktiengesellschaft Price
Bayer Aktiengesellschaft Price | Bayer Aktiengesellschaft Quote
Zacks Rank and Other Key Picks
Bayer currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the same space are AstraZeneca Plc. AZN and BioDelivery Bristol-Myers Squibb Company BMY, each carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AstraZeneca’s earnings per share estimates have increased from $1.76 to $1.79 for 2019 and from $1.99 to $2.19 for 2020 in the past 90 days. The company delivered a positive earnings surprise in all the trailing four quarters, with average of 106.40%.
Bristol-Myers’ earnings per share estimates have increased from $4.12 to $4.16 for 2019 and from $4.36 to $4.64 for 2020 over the past 90 days. The company delivered a positive earnings surprise in all the trailing four quarters, with average of 14.26%.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year? Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ) : Free Stock Analysis Report
AstraZeneca PLC (AZN) : Free Stock Analysis Report
Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report
Bristol-Myers Squibb Company (BMY) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research